Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALDOSE-1: IMU-838 dose-finding study in moderate-to-severe ulcerative colitis
NL-OMON55843Phase 2Recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in autoimmune colitis (5 arms), sponsored by Immunic Therapeutics. Primary endpoint: Composite remission and healing at Week 10. Started Jan 2019; status: recruiting.
02
Drugs
vidofludimus calcium
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON55843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55843.